First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo

First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo

283121

First Patient Dosed in Phase 3 Trial Testing Melflufen Triple Combo

The first participant has been dosed in a Phase 3 trial investigating a triple combination of melflufen (melphalan flufenamide) plus dexamethasone and under-the-skin Darzalex (daratumumab) in people with heavily treated multiple myeloma. The trial, dubbed LIGHTHOUSE (NCT04649060), had been delayed by the COVID-19 pandemic but is now recruiting an estimated 240 participants, ages 18 and older, at two locations in the Czech Republic. “There is an imminent need for additional therapeutic options as myeloma patients…

You must be logged in to read/download the full post.